{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:58:00Z","timestamp":1782925080477,"version":"3.54.5"},"posted":{"date-parts":[[2026,4,6]]},"group-title":"In Review","reference-count":11,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,17]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n  Current treatment guidelines for rheumatoid arthritis (RA) favor discontinuation of methotrexate (MTX) over biologic (b) DMARDs.  To assess acceptability of this approach, we conducted a cross-sectional study evaluating the perspectives of patients and providers on MTX tapering at one urban and one rural health care center.\nMethods\n Rheumatologists and patients were surveyed at the two health centers, one in an urban location and one with a predominantly rural service area. Patient surveys collected demographics, history of MTX use, and views on tapering. Provider surveys included questions about years of rheumatology practice and strategies being employed for tapering. Data were analyzed using chi-square and Wilcoxon rank sum tests in both questionnaire groups.\nResults\n Surveys were collected over a 3 year period, from January 2020 through the end of 2022. Of the 143 patient respondents, 78% female and 86% were White. Median duration of RA was 12 years. Tapering trials of MTX were more frequent at the urban facility (p\u2009=\u20090.02) and were more often considered in males with stable disease activity (p\u2009=\u20090.005, and p\u2009=\u20090.042,) and those with longer disease duration. Tapering concerns were greater for female patients on MTX for at least 8 years (p\u2009=\u20090.046). Surveys collected from 16 urban providers and 8 rural providers showed that those with less than 15 years of experience were more likely to consider tapering if patients were concurrently on other treatments favorable for tapering (p\u2009=\u20090.019) and were likely to consider patient preferences against tapering (p\u2009=\u20090.004). None of the other differences between the two centers were significant.\nConclusion\n We identified factors influencing tapering decisions for both patients and rheumatology providers, including age, race, sex, RA duration and provider\u2019s years of experience. Consideration of these will facilitate designing acceptable future approaches to MTX tapering in patients with stable RA.<\/p>","DOI":"10.21203\/rs.3.rs-9142998\/v1","type":"posted-content","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:42:04Z","timestamp":1775486524000},"source":"Crossref","is-referenced-by-count":0,"title":["Tapering or Discontinuation of Methotrexate in Stable Disease- Opinions From Rheumatoid Arthritis Patients and Rheumatology Providers at Two Academic Healthcare Centers"],"prefix":"10.21203","author":[{"given":"Peri","family":"Newman","sequence":"first","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Sharma","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayford","family":"June","sequence":"additional","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wilson","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glennys","family":"Smith","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lehman","sequence":"additional","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Rai","sequence":"additional","affiliation":[{"name":"Allegheny Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Olsen","sequence":"additional","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Banks","sequence":"additional","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"9285","key":"ref1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee DM","year":"2001","unstructured":"Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903\u201311.","journal-title":"Lancet"},{"issue":"10416","key":"ref2","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Matteo A","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019\u201333.","journal-title":"Lancet"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"e2345132","DOI":"10.1001\/jamanetworkopen.2023.45132","article-title":"Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease","volume":"6","author":"Muanda FT","year":"2023","unstructured":"Muanda FT, Blake PG, Weir MA, et al. Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease. JAMA Netw Open. 2023;6(11):e2345132.","journal-title":"JAMA Netw Open"},{"key":"ref5","author":"Hanoodi M","year":"2025","unstructured":"Hanoodi M, Mittal M, Methotrexate. 2025. In: StatPearls [Internet] [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556114\/"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S2665-9913(24)00021-3","article-title":"Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (arctic rewind): 3-year results from an open-label, randomised controlled, non-inferiority trial","volume":"6","author":"Kjorholt KE","year":"2024","unstructured":"Kjorholt KE, Sundlisaeter NP, Aga AB, et al. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (arctic rewind): 3-year results from an open-label, randomised controlled, non-inferiority trial. Lancet Rheumatol. 2024;6(5):e268\u201378.","journal-title":"Lancet Rheumatol"},{"issue":"Suppl4","key":"ref7","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/kead410","article-title":"Medication tapering in stable rheumatoid arthritis: Where do we stand and what work needs to be done?","volume":"62","author":"Sharma T","year":"2023","unstructured":"Sharma T, Banks S. Medication tapering in stable rheumatoid arthritis: Where do we stand and what work needs to be done? Rheumatology (Oxford). 2023;62(Suppl4):iv1\u20132.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/keab330","article-title":"Patient and rheumatologist perspectives on tapering dmards in rheumatoid arthritis: A qualitative study","volume":"61","author":"Hazlewood GS","year":"2022","unstructured":"Hazlewood GS, Loyola-Sanchez A, Bykerk V, et al. Patient and rheumatologist perspectives on tapering dmards in rheumatoid arthritis: A qualitative study. Rheumatology (Oxford). 2022;61(2):606\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl4","key":"ref9","doi-asserted-by":"crossref","first-page":"iv3","DOI":"10.1093\/rheumatology\/kead431","article-title":"Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives","volume":"62","author":"Wiemer N","year":"2023","unstructured":"Wiemer N, Webster P, Attur M, et al. Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives. Rheumatology (Oxford). 2023;62(Suppl4):iv3\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/BOR.0000000000000591","article-title":"Patient preferences for rheumatoid arthritis treatment","volume":"31","author":"Hsiao B","year":"2019","unstructured":"Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol. 2019;31(3):256\u201363.","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl4","key":"ref11","doi-asserted-by":"crossref","first-page":"iv8","DOI":"10.1093\/rheumatology\/kead430","article-title":"A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (rheumtap) cohort","volume":"62","author":"Tageldin M","year":"2023","unstructured":"Tageldin M, Wilson N, Yin Y, Sharma TS. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (rheumtap) cohort. Rheumatology (Oxford). 2023;62(Suppl4):iv8\u201313.","journal-title":"Rheumatology (Oxford)"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9142998\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9142998\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:41:56Z","timestamp":1782924116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9142998\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":11,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9142998\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s41927-026-00667-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,4,6]]},"subtype":"preprint"}}